Objectives

After participating in this educational activity, attendees should be able to:
1. Understand the measurement of outcomes in the treatment of radioiodine-refractory thyroid cancer
2. Describe the common toxicities of tyrosine kinase inhibitors used in the therapy of thyroid cancer
3. Describe the commonly used TKIs in thyroid cancer management

Faculty

Wilson C. Mertens, MD, MSBA
Vice President and Medical Director, Cancer Services
Chief, Division of Hematology Oncology
Physician
Baystate Medical Center 

Faculty Disclosure
None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.